Click for best price
Drugs Diagnostics for Hematological Disorders Market Size, Share 2022
Hematological disorders deal with blood related diseases and generally affect the quantity or functionality of the cells or proteins present in the blood.
This report contains market size and forecasts of Drugs and Diagnostics for Hematological Disorders in Global, including the following market information:
Global Drugs and Diagnostics for Hematological Disorders Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Drugs and Diagnostics for Hematological Disorders market was valued at 97320 million in 2021 and is projected to reach US$ 128670 million by 2028, at a CAGR of 4.1% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Analyzers Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Drugs and Diagnostics for Hematological Disorders include Abbot, Pfizer, Amgen, Beckman Coulter, Mindray, Roche, Biorad, Eli Lilly and Sysmex, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Drugs and Diagnostics for Hematological Disorders companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drugs and Diagnostics for Hematological Disorders Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Drugs and Diagnostics for Hematological Disorders Market Segment Percentages, by Type, 2021 (%)
Analyzers
Reagents
Global Drugs and Diagnostics for Hematological Disorders Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Drugs and Diagnostics for Hematological Disorders Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Others
Global Drugs and Diagnostics for Hematological Disorders Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Drugs and Diagnostics for Hematological Disorders Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drugs and Diagnostics for Hematological Disorders revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Drugs and Diagnostics for Hematological Disorders revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Abbot
Pfizer
Amgen
Beckman Coulter
Mindray
Roche
Biorad
Eli Lilly
Sysmex
Bristol-Myers
Siemens
Horbia
Nihon Kohden
| Report Attributes |
Report Details |
| Report Title |
Drugs and Diagnostics for Hematological Disorders Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
66 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Drugs and Diagnostics for Hematological Disorders Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drugs and Diagnostics for Hematological Disorders Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drugs and Diagnostics for Hematological Disorders Overall Market Size
2.1 Global Drugs and Diagnostics for Hematological Disorders Market Size: 2021 VS 2028
2.2 Global Drugs and Diagnostics for Hematological Disorders Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Drugs and Diagnostics for Hematological Disorders Players in Global Market
3.2 Top Global Drugs and Diagnostics for Hematological Disorders Companies Ranked by Revenue
3.3 Global Drugs and Diagnostics for Hematological Disorders Revenue by Companies
3.4 Top 3 and Top 5 Drugs and Diagnostics for Hematological Disorders Companies in Global Market, by Revenue in 2021
3.5 Global Companies Drugs and Diagnostics for Hematological Disorders Product Type
3.6 Tier 1, Tier 2 and Tier 3 Drugs and Diagnostics for Hematological Disorders Players in Global Market
3.6.1 List of Global Tier 1 Drugs and Diagnostics for Hematological Disorders Companies
3.6.2 List of Global Tier 2 and Tier 3 Drugs and Diagnostics for Hematological Disorders Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Drugs and Diagnostics for Hematological Disorders Market Size Markets, 2021 & 2028
4.1.2 Analyzers
4.1.3 Reagents
4.2 By Type - Global Drugs and Diagnostics for Hematological Disorders Revenue & Forecasts
4.2.1 By Type - Global Drugs and Diagnostics for Hematological Disorders Revenue, 2017-2022
4.2.2 By Type - Global Drugs and Diagnostics for Hematological Disorders Revenue, 2023-2028
4.2.3 By Type - Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Drugs and Diagnostics for Hematological Disorders Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application - Global Drugs and Diagnostics for Hematological Disorders Revenue & Forecasts
5.2.1 By Application - Global Drugs and Diagnostics for Hematological Disorders Revenue, 2017-2022
5.2.2 By Application - Global Drugs and Diagnostics for Hematological Disorders Revenue, 2023-2028
5.2.3 By Application - Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Drugs and Diagnostics for Hematological Disorders Market Size, 2021 & 2028
6.2 By Region - Global Drugs and Diagnostics for Hematological Disorders Revenue & Forecasts
6.2.1 By Region - Global Drugs and Diagnostics for Hematological Disorders Revenue, 2017-2022
6.2.2 By Region - Global Drugs and Diagnostics for Hematological Disorders Revenue, 2023-2028
6.2.3 By Region - Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Drugs and Diagnostics for Hematological Disorders Revenue, 2017-2028
6.3.2 US Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.3.3 Canada Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.3.4 Mexico Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Drugs and Diagnostics for Hematological Disorders Revenue, 2017-2028
6.4.2 Germany Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.4.3 France Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.4.4 U.K. Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.4.5 Italy Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.4.6 Russia Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.4.7 Nordic Countries Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.4.8 Benelux Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Drugs and Diagnostics for Hematological Disorders Revenue, 2017-2028
6.5.2 China Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.5.3 Japan Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.5.4 South Korea Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.5.5 Southeast Asia Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.5.6 India Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Drugs and Diagnostics for Hematological Disorders Revenue, 2017-2028
6.6.2 Brazil Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.6.3 Argentina Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Drugs and Diagnostics for Hematological Disorders Revenue, 2017-2028
6.7.2 Turkey Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.7.3 Israel Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.7.4 Saudi Arabia Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
6.7.5 UAE Drugs and Diagnostics for Hematological Disorders Market Size, 2017-2028
7 Players Profiles
7.1 Abbot
7.1.1 Abbot Corporate Summary
7.1.2 Abbot Business Overview
7.1.3 Abbot Drugs and Diagnostics for Hematological Disorders Major Product Offerings
7.1.4 Abbot Drugs and Diagnostics for Hematological Disorders Revenue in Global Market (2017-2022)
7.1.5 Abbot Key News
7.2 Pfizer
7.2.1 Pfizer Corporate Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Drugs and Diagnostics for Hematological Disorders Major Product Offerings
7.2.4 Pfizer Drugs and Diagnostics for Hematological Disorders Revenue in Global Market (2017-2022)
7.2.5 Pfizer Key News
7.3 Amgen
7.3.1 Amgen Corporate Summary
7.3.2 Amgen Business Overview
7.3.3 Amgen Drugs and Diagnostics for Hematological Disorders Major Product Offerings
7.3.4 Amgen Drugs and Diagnostics for Hematological Disorders Revenue in Global Market (2017-2022)
7.3.5 Amgen Key News
7.4 Beckman Coulter
7.4.1 Beckman Coulter Corporate Summary
7.4.2 Beckman Coulter Business Overview
7.4.3 Beckman Coulter Drugs and Diagnostics for Hematological Disorders Major Product Offerings
7.4.4 Beckman Coulter Drugs and Diagnostics for Hematological Disorders Revenue in Global Market (2017-2022)
7.4.5 Beckman Coulter Key News
7.5 Mindray
7.5.1 Mindray Corporate Summary
7.5.2 Mindray Business Overview
7.5.3 Mindray Drugs and Diagnostics for Hematological Disorders Major Product Offerings
7.5.4 Mindray Drugs and Diagnostics for Hematological Disorders Revenue in Global Market (2017-2022)
7.5.5 Mindray Key News
7.6 Roche
7.6.1 Roche Corporate Summary
7.6.2 Roche Business Overview
7.6.3 Roche Drugs and Diagnostics for Hematological Disorders Major Product Offerings
7.6.4 Roche Drugs and Diagnostics for Hematological Disorders Revenue in Global Market (2017-2022)
7.6.5 Roche Key News
7.7 Biorad
7.7.1 Biorad Corporate Summary
7.7.2 Biorad Business Overview
7.7.3 Biorad Drugs and Diagnostics for Hematological Disorders Major Product Offerings
7.7.4 Biorad Drugs and Diagnostics for Hematological Disorders Revenue in Global Market (2017-2022)
7.7.5 Biorad Key News
7.8 Eli Lilly
7.8.1 Eli Lilly Corporate Summary
7.8.2 Eli Lilly Business Overview
7.8.3 Eli Lilly Drugs and Diagnostics for Hematological Disorders Major Product Offerings
7.8.4 Eli Lilly Drugs and Diagnostics for Hematological Disorders Revenue in Global Market (2017-2022)
7.8.5 Eli Lilly Key News
7.9 Sysmex
7.9.1 Sysmex Corporate Summary
7.9.2 Sysmex Business Overview
7.9.3 Sysmex Drugs and Diagnostics for Hematological Disorders Major Product Offerings
7.9.4 Sysmex Drugs and Diagnostics for Hematological Disorders Revenue in Global Market (2017-2022)
7.9.5 Sysmex Key News
7.10 Bristol-Myers
7.10.1 Bristol-Myers Corporate Summary
7.10.2 Bristol-Myers Business Overview
7.10.3 Bristol-Myers Drugs and Diagnostics for Hematological Disorders Major Product Offerings
7.10.4 Bristol-Myers Drugs and Diagnostics for Hematological Disorders Revenue in Global Market (2017-2022)
7.10.5 Bristol-Myers Key News
7.11 Siemens
7.11.1 Siemens Corporate Summary
7.11.2 Siemens Business Overview
7.11.3 Siemens Drugs and Diagnostics for Hematological Disorders Major Product Offerings
7.11.4 Siemens Drugs and Diagnostics for Hematological Disorders Revenue in Global Market (2017-2022)
7.11.5 Siemens Key News
7.12 Horbia
7.12.1 Horbia Corporate Summary
7.12.2 Horbia Business Overview
7.12.3 Horbia Drugs and Diagnostics for Hematological Disorders Major Product Offerings
7.12.4 Horbia Drugs and Diagnostics for Hematological Disorders Revenue in Global Market (2017-2022)
7.12.5 Horbia Key News
7.13 Nihon Kohden
7.13.1 Nihon Kohden Corporate Summary
7.13.2 Nihon Kohden Business Overview
7.13.3 Nihon Kohden Drugs and Diagnostics for Hematological Disorders Major Product Offerings
7.13.4 Nihon Kohden Drugs and Diagnostics for Hematological Disorders Revenue in Global Market (2017-2022)
7.13.5 Nihon Kohden Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Drugs and Diagnostics for Hematological Disorders Market Opportunities & Trends in Global Market
Table 2. Drugs and Diagnostics for Hematological Disorders Market Drivers in Global Market
Table 3. Drugs and Diagnostics for Hematological Disorders Market Restraints in Global Market
Table 4. Key Players of Drugs and Diagnostics for Hematological Disorders in Global Market
Table 5. Top Drugs and Diagnostics for Hematological Disorders Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Drugs and Diagnostics for Hematological Disorders Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Drugs and Diagnostics for Hematological Disorders Revenue Share by Companies, 2017-2022
Table 8. Global Companies Drugs and Diagnostics for Hematological Disorders Product Type
Table 9. List of Global Tier 1 Drugs and Diagnostics for Hematological Disorders Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drugs and Diagnostics for Hematological Disorders Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Drugs and Diagnostics for Hematological Disorders Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Drugs and Diagnostics for Hematological Disorders Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Drugs and Diagnostics for Hematological Disorders Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Drugs and Diagnostics for Hematological Disorders Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Drugs and Diagnostics for Hematological Disorders Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Drugs and Diagnostics for Hematological Disorders Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2023-2028
Table 30. Abbot Corporate Summary
Table 31. Abbot Drugs and Diagnostics for Hematological Disorders Product Offerings
Table 32. Abbot Drugs and Diagnostics for Hematological Disorders Revenue (US$, Mn), (2017-2022)
Table 33. Pfizer Corporate Summary
Table 34. Pfizer Drugs and Diagnostics for Hematological Disorders Product Offerings
Table 35. Pfizer Drugs and Diagnostics for Hematological Disorders Revenue (US$, Mn), (2017-2022)
Table 36. Amgen Corporate Summary
Table 37. Amgen Drugs and Diagnostics for Hematological Disorders Product Offerings
Table 38. Amgen Drugs and Diagnostics for Hematological Disorders Revenue (US$, Mn), (2017-2022)
Table 39. Beckman Coulter Corporate Summary
Table 40. Beckman Coulter Drugs and Diagnostics for Hematological Disorders Product Offerings
Table 41. Beckman Coulter Drugs and Diagnostics for Hematological Disorders Revenue (US$, Mn), (2017-2022)
Table 42. Mindray Corporate Summary
Table 43. Mindray Drugs and Diagnostics for Hematological Disorders Product Offerings
Table 44. Mindray Drugs and Diagnostics for Hematological Disorders Revenue (US$, Mn), (2017-2022)
Table 45. Roche Corporate Summary
Table 46. Roche Drugs and Diagnostics for Hematological Disorders Product Offerings
Table 47. Roche Drugs and Diagnostics for Hematological Disorders Revenue (US$, Mn), (2017-2022)
Table 48. Biorad Corporate Summary
Table 49. Biorad Drugs and Diagnostics for Hematological Disorders Product Offerings
Table 50. Biorad Drugs and Diagnostics for Hematological Disorders Revenue (US$, Mn), (2017-2022)
Table 51. Eli Lilly Corporate Summary
Table 52. Eli Lilly Drugs and Diagnostics for Hematological Disorders Product Offerings
Table 53. Eli Lilly Drugs and Diagnostics for Hematological Disorders Revenue (US$, Mn), (2017-2022)
Table 54. Sysmex Corporate Summary
Table 55. Sysmex Drugs and Diagnostics for Hematological Disorders Product Offerings
Table 56. Sysmex Drugs and Diagnostics for Hematological Disorders Revenue (US$, Mn), (2017-2022)
Table 57. Bristol-Myers Corporate Summary
Table 58. Bristol-Myers Drugs and Diagnostics for Hematological Disorders Product Offerings
Table 59. Bristol-Myers Drugs and Diagnostics for Hematological Disorders Revenue (US$, Mn), (2017-2022)
Table 60. Siemens Corporate Summary
Table 61. Siemens Drugs and Diagnostics for Hematological Disorders Product Offerings
Table 62. Siemens Drugs and Diagnostics for Hematological Disorders Revenue (US$, Mn), (2017-2022)
Table 63. Horbia Corporate Summary
Table 64. Horbia Drugs and Diagnostics for Hematological Disorders Product Offerings
Table 65. Horbia Drugs and Diagnostics for Hematological Disorders Revenue (US$, Mn), (2017-2022)
Table 66. Nihon Kohden Corporate Summary
Table 67. Nihon Kohden Drugs and Diagnostics for Hematological Disorders Product Offerings
Table 68. Nihon Kohden Drugs and Diagnostics for Hematological Disorders Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Drugs and Diagnostics for Hematological Disorders Segment by Type in 2021
Figure 2. Drugs and Diagnostics for Hematological Disorders Segment by Application in 2021
Figure 3. Global Drugs and Diagnostics for Hematological Disorders Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Drugs and Diagnostics for Hematological Disorders Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Drugs and Diagnostics for Hematological Disorders Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Drugs and Diagnostics for Hematological Disorders Revenue in 2021
Figure 8. By Type - Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share, 2017-2028
Figure 9. By Application - Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share, 2017-2028
Figure 10. By Region - Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share, 2017-2028
Figure 11. By Country - North America Drugs and Diagnostics for Hematological Disorders Revenue Market Share, 2017-2028
Figure 12. US Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Drugs and Diagnostics for Hematological Disorders Revenue Market Share, 2017-2028
Figure 16. Germany Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 17. France Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Drugs and Diagnostics for Hematological Disorders Revenue Market Share, 2017-2028
Figure 24. China Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 28. India Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Drugs and Diagnostics for Hematological Disorders Revenue Market Share, 2017-2028
Figure 30. Brazil Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Drugs and Diagnostics for Hematological Disorders Revenue Market Share, 2017-2028
Figure 33. Turkey Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Drugs and Diagnostics for Hematological Disorders Revenue, (US$, Mn), 2017-2028
Figure 37. Abbot Drugs and Diagnostics for Hematological Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Pfizer Drugs and Diagnostics for Hematological Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Amgen Drugs and Diagnostics for Hematological Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Beckman Coulter Drugs and Diagnostics for Hematological Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Mindray Drugs and Diagnostics for Hematological Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Roche Drugs and Diagnostics for Hematological Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Biorad Drugs and Diagnostics for Hematological Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Eli Lilly Drugs and Diagnostics for Hematological Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Sysmex Drugs and Diagnostics for Hematological Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Bristol-Myers Drugs and Diagnostics for Hematological Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Siemens Drugs and Diagnostics for Hematological Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Horbia Drugs and Diagnostics for Hematological Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Nihon Kohden Drugs and Diagnostics for Hematological Disorders Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
